Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000114040 | SCV000301346 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Ambry Genetics | RCV000222600 | SCV000277479 | pathogenic | Hereditary cancer-predisposing syndrome | 2015-08-05 | criteria provided, single submitter | clinical testing | The c.9069_9076delTAACATAC pathogenic mutation (also known as 9297del8), located in coding exon 22 of the BRCA2 gene, results from a deletion of 8 nucleotides between positions 9069 and 9076, causing a translational frameshift with a predicted alternate stop codon. This mutation (referred to as 9297del8) was seen once in a cohort of 107 families from Scotland and Northern Ireland suspected to have BRCA1/2 mutations (Br. J. Cancer 2003 Apr; 88(8):1256-62). In addition to the clinical data presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000114040 | SCV000328040 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Breast Cancer Information Core |
RCV000114040 | SCV000147527 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | no assertion criteria provided | clinical testing | ||
Research Molecular Genetics Laboratory, |
RCV000496562 | SCV000587985 | pathogenic | Hereditary breast ovarian cancer syndrome | 2014-01-31 | no assertion criteria provided | research |